Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery

Autor: Dominik C. Bader, Enrico N. De Toni, Lydia Kriegl, Sabina Berezowska, Burkhard Göke, Thomas Kirchner, Eike Gallmeier, Hendrik Seeliger, Christiane J. Bruns
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
Colorectal cancer
Cancer Treatment
Kaplan-Meier Estimate
Metastasis
Surgical oncology
Gastrointestinal Cancers
610 Medicine & health
Multidisciplinary
Middle Aged
Prognosis
Immunohistochemistry
medicine.anatomical_structure
Oncology
Lymphatic Metastasis
Medicine
CA19-9
Female
Pancreas
Cancer Screening
Carcinoma
Pancreatic Ductal
Research Article
medicine.medical_specialty
Science
Gastroenterology and Hepatology
Therapeutic approach
Pancreatic Cancer
Antibody Therapy
Pancreatic cancer
Gastrointestinal Tumors
medicine
Cancer Detection and Diagnosis
Early Detection
Humans
Aged
Staining and Labeling
business.industry
Cell Membrane
Cancer
Cancers and Neoplasms
medicine.disease
Surgery
Pancreatic Neoplasms
Receptors
TNF-Related Apoptosis-Inducing Ligand
570 Life sciences
biology
Lymph Nodes
business
Zdroj: PLoS ONE, Vol 8, Iss 2, p e56760 (2013)
PLoS ONE
Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina Anna; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N. (2013). Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS ONE, 8(2), e56760. Public Library of Science 10.1371/journal.pone.0056760
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0056760
Popis: IntroductionAgonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been sufficiently investigated and no study has yet addressed the issue of their prognostic significance in this tumor entity.Aims and methodsApplying tissue microarray (TMA) analysis, we performed an immunohistochemical assessment of TRAIL-receptors in surgical samples from 84 consecutive patients affected by pancreatic adenocarcinoma and in 26 additional selected specimens from patients with no lymph nodes metastasis at the time of surgery. The prognostic significance of membrane staining and staining intensity for TRAIL-receptors was evaluated.ResultsThe fraction of pancreatic cancer samples with positive membrane staining for TRAIL-R1 and TRAIL-R2 was lower than that of cells from surrounding non-tumor tissues (TRAIL-R1: pConclusionThis is a first report on the prognostic significance of TRAIL-receptors expression in pancreatic cancer showing that TRAIL-R2 might represent a prognostic marker for patients with early stage disease. In addition, our data suggest that loss of membrane-bound TRAIL-receptors could represent a molecular mechanism for therapeutic failure upon administration of TRAIL-receptors-targeting antibodies in pancreatic cancer. This hypothesis should be evaluated in future clinical trials.
Databáze: OpenAIRE
Externí odkaz: